Business · 22/04/2026
FDA Classifies Alzheimer's Disease Pathology Assessment Test as Class II Device
The FDA has classified the Alzheimer's disease pathology assessment test as a Class II device, which will provide a reasonable assurance of safety and effectiveness, and reduce regulatory burdens, ultimately enhancing patients' access to innovative devices.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →